文献类型：期刊文献

中文题名：连花清瘟联合西医治疗新型冠状病毒肺炎临床疗效的Meta分析

英文题名：Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by Meta-analysis

作者：王淑霞[1];李明阳[1];陈雪莲[1];马明艳[1];胡继宏[2]

第一作者：王淑霞

机构：[1]甘肃中医药大学公共卫生学院,甘肃兰州730000;[2]甘肃中医药大学科研实验中心,甘肃兰州730000

第一机构：甘肃中医药大学公共卫生学院

年份：2020

卷号：51

期号：14

起止页码：3763

中文期刊名：中草药

外文期刊名：Chinese Traditional and Herbal Drugs

收录：CSTPCD;;Scopus;北大核心:【北大核心2017】；CSCD:【CSCD2019_2020】；

基金：国家自然科学基金资助项目(81960614)。

语种：中文

中文关键词：连花清瘟;新型冠状病毒肺炎(COVID-19);Meta分析;疗效;中西医结合

外文关键词：Lianhua Qingwen;novel coronavirus disease(COVID-19);Meta-analysis;efficacy;integrated Chinese and western medicine

摘要：目的系统评价连花清瘟治疗新型冠状病毒肺炎(coronavirusdisease,COVID-19)的疗效情况,为COVID-19临床治疗提供依据。方法计算机检索中国知网、万方、维普、CBM、PubMed及Cochrane Library等数据库,检索时间截至2020年5月27日。采用Cochrane协作网偏倚风险工具对纳入研究进行风险评估及质量评价,Stata 15软件进行Meta分析,Begg’s检验分析发表偏倚。结果最终纳入7项临床疗效研究,包括665例COVID-19患者。Meta分析结果显示,与西医单独治疗相比,连花清瘟联合西医治疗可明显改善COVID-19患者的主要临床症状有效率[RR=1.24,95%CI(1.12,1.38),P<0.05],CT好转情况[RR=1.14, 95%CI (1.02, 1.28),P<0.05]及降低临床转重型比例[RR=0.48,95%CI(0.31,0.72),P<0.05];此外,连花清瘟联合治疗可有效缩短COVID-19患者的发热持续时间[SMD=-0.87,95%CI(-1.22,-0.52),P<0.05]、临床症状消失时间[SMD=-1.19,95%CI(-1.56,-0.82),P<0.05]及住院时间[SMD=-0.61,95%CI(-0.91,-0.30),P<0.05]。结论连花清瘟作为辅助治疗可有效改善COVID-19患者的临床症状及CT好转情况。
Objective To systematically evaluate the efficacy of Lianhua Qingwen(LQC) on COVID-19, and provide evidence for the formulation and optimization of clinical therapy on COVID-19. Methods Six databases(PubMed, Cochrane Library, Wanfang, Weipu, CBM and CNKI) were searched up to May 27, 2020. The Cochrane collaborative bias risk tool was used for risk evaluation and quality assessment;Meta-analysis was carried out by Stata 15 software. Begg’s test was used for publication bias. Results Seven clinical trials were included with 665 COVID-19 patients. Compared with Western medicine alone, integrated Lianhua Qingwen significantly improved the effective rate of clinical symptoms [RR = 1.24, 95% CI(1.12, 1.38), P < 0.05] of COVID-19, increased CT improvement [RR = 1.14, 95% CI(1.02, 1.28), P < 0.05] and reduced the proportion of progressing into sever clinical level [RR = 0.48, 95% CI(0.31, 0.72), P < 0.05];In addition, integrated Lianhua Qingwen could effectively shorten the duration of fever [SMD =-0.87, 95% CI(-1.22,-0.52), P < 0.05], time of clinical symptoms disappearance [SMD =-1.19, 95% CI(-1.56,-0.82), P < 0.05] and hospital stay [SMD =-0.61, 95% CI(-0.91,-0.30), P < 0.05]. Conclusion Lianhua Qingwen could be used as adaptive and complementary medicine to improve clinical symptoms and CT for COVID-19.